Navigating key decisions in NMIBC care

By Megan Lee

NMIBC decision‑making requires balancing individual risk features, available treatment resources, and the patient’s personal goals and preferences

Decision-making in non–muscle-invasive bladder cancer (NMIBC) is complex and highly individualized. Clinicians must balance tumor biology, guideline-defined risk, treatment availability (e.g., shortages of bacillus Calmette–Guérin [BCG]), and patient priorities. In practice, clinicians must navigate these challenges within their local constraints, applying a risk-aligned approach to support evidence-based, individualized decision-making despite ongoing uncertainty.

How should clinicians approach inconsistent NMIBC risk stratification?

Despite the existing variations between guideline groups, the core purpose of risk stratification in NMIBC remains the same: to guide treatment intensity and surveillance based on the likelihood of recurrence and progression.

Experts recognize the importance of:

• Applying low-, intermediate-, and high‑risk groupings thoughtfully to support consistent treatment decisions, while recognizing that rigid adherence to any single framework may not reflect real-world complexity
• Intermediate‑risk NMIBC as a broad category, where factors such as tumor size, multiplicity, grade, and prior recurrence patterns often need to be weighed together to refine treatment decisions
• Patient characteristics and their central role in shaping appropriate care pathways, including age, comorbidities, functional status, and personal priorities
• Applying reliable delivery of intravesical therapy and surveillance by using structured workflows that help teams maintain timely instillations and follow‑up

Which clinical features most strongly influence NMIBC recurrence and progression?

Several tumor-related and pathological features are consistently associated with a higher likelihood of recurrence or progression in NMIBC. Recognizing these indicators helps clinicians judge when to escalate intravesical therapy, consider early cystectomy, or adjust surveillance schedules based on individual risk.

Key clinical indicators:

• High-grade and T1 tumors carry an increased risk of progression to muscle-invasive disease and may prompt consideration of intensified intravesical therapy or earlier discussion of radical treatment options
• The presence of carcinoma in situ (CIS) increases progression risk, often shifting the balance between continued bladder-preserving approaches and more definitive intervention
• Lymphovascular invasion, multiple T1 tumors, large lesions, or involvement of high-risk locations like the prostatic urethra can inform decisions around closer monitoring and treatment escalation

How do BCG shortages and administration challenges affect NMIBC treatment planning?

Variability in BCG availability and practical delivery challenges continue to affect NMIBC treatment planning.

Experts highlight that:

• Limited BCG supply may result in some patients receiving fewer instillations than planned, requiring clinicians to prioritize certain patients or modify treatment schedules. Inconsistent delivery can also complicate decisions around maintenance therapy
• Patient concerns, side effects, and misunderstandings about BCG can delay, interrupt, or stop BCG courses
• Real-world workflow pressures – such as scheduling constraints and resource limitations – can affect the timely delivery of intravesical therapy and surveillance

How should patient and caregiver priorities be integrated into NMIBC decision-making?

Patient and caregiver experiences show how fear of recurrence, anxiety about surveillance, treatment burden, and quality-of-life trade-offs influence NMIBC decision‑making. Understanding these priorities helps clinicians match treatment intensity to individual needs and capacity.

Important factors:

• Many patients prioritize survival above all else, while others may value bladder preservation or reduced treatment burden more highly
• Living with ongoing surveillance and uncertainty can create significant emotional strain, affecting both patients and caregivers
• Caregivers often play a key role in supporting appointments, monitoring symptoms, and helping patients navigate complex care pathways
• Clear, empathetic communication about risks, expectations, and options is key to effective shared decision-making